A detailed history of Gts Securities LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Gts Securities LLC holds 5,497 shares of APLS stock, worth $210,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,497
Previous 221,600 97.52%
Holding current value
$210,864
Previous $13.3 Million 97.56%
% of portfolio
0.0%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$55.39 - $72.47 $2.58 Million - $3.37 Million
-46,550 Reduced 89.44%
5,497 $323,000
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $566,496 - $988,699
15,253 Added 41.46%
52,047 $3.12 Million
Q3 2023

Nov 15, 2023

BUY
$23.65 - $89.22 $531,297 - $2 Million
22,465 Added 156.78%
36,794 $1.4 Million
Q2 2023

Aug 15, 2023

BUY
$76.68 - $93.31 $1.1 Million - $1.34 Million
14,329 New
14,329 $1.31 Billion

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.21B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.